Form 4: Lantern Pharma Director Vijay Chandru Granted Stock Options

Director Vijay Chandru received two stock option grants from Lantern Pharma, vesting over 24 and 36 months respectively.

Summary

• Vijay Chandru, a director of Lantern Pharma Inc., was granted two stock option awards on July 15, 2024.
• Each option grant is for 5,000 shares of common stock, with an exercise price of $4.35 per share.
• The first option grant vests in equal monthly increments over 24 months, commencing August 15, 2024.
• The second option grant vests in equal monthly increments over 36 months, commencing August 15, 2024.
• Both option grants expire on July 15, 2034.
• Following the transaction, Chandru directly owns 5,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules of 24 to 36 months are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Relay Therapeutics or Black Diamond Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the director to work towards increasing shareholder value.

Key Dates